AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Overview
Authors
Affiliations
Background & Aims: Pharmacological management of obesity improves outcomes and decreases the risk of obesity-related complications. This American Gastroenterological Association guideline is intended to support practitioners in decisions about pharmacological interventions for overweight and obesity.
Methods: A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation framework to prioritize clinical questions, identify patient-centered outcomes, and conduct an evidence synthesis of the following agents: semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate extended-release (ER), naltrexone-bupropion ER, orlistat, phentermine, diethylpropion, and Gelesis100 oral superabsorbent hydrogel. The guideline panel used the evidence-to-decision framework to develop recommendations for the pharmacological management of obesity and provided implementation considerations for clinical practice.
Results: The guideline panel made 9 recommendations. The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m, or ≥27 kg/m with weight-related complications) who have an inadequate response to lifestyle interventions. The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity. The guideline panel suggested against the use of orlistat. The panel identified the use of Gelesis100 oral superabsorbent hydrogel as a knowledge gap.
Conclusions: In adults with overweight and obesity who have an inadequate response to lifestyle interventions alone, long-term pharmacological therapy is recommended, with multiple effective and safe treatment options.
Hospitalist Recognition and Treatment of Obesity in Inpatients: A Quality Improvement Cohort Study.
Hoppenfeld M, Moss J, Johnson S J Brown Hosp Med. 2025; 3(2):94545.
PMID: 40026791 PMC: 11864445. DOI: 10.56305/001c.94545.
Cheng Y, Bullard K, Hora I, Belay B, Xu F, Holliday C BMJ Open Diabetes Res Care. 2025; 13(1).
PMID: 39965869 PMC: 11836783. DOI: 10.1136/bmjdrc-2024-004614.
Liu L, Li Z, Ye W, Peng P, Wang Y, Wan L EClinicalMedicine. 2025; 79():103020.
PMID: 39834714 PMC: 11743856. DOI: 10.1016/j.eclinm.2024.103020.
Yahia Y, Abuodeh J, Chandra P, Mohamed E, Zayad A, AbuAfifeh L Obes Surg. 2025; 35(2):496-504.
PMID: 39806256 PMC: 11836173. DOI: 10.1007/s11695-024-07647-x.
Ischemic Jejunitis as a Late Complication of Roux-en-Y Gastric Bypass.
Kimchy A, Khambaty F, Marino G ACG Case Rep J. 2025; 12(1):e01591.
PMID: 39781182 PMC: 11709216. DOI: 10.14309/crj.0000000000001591.